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Background
Rapid and accurate estimation of the glomerular filtation
rate (GFR) is required for many major clinical decisions in
patients with chronic nephropathies [1]. Direct GFR
measurement is time-consuming and expensive, fre-
quently requires urine collection and isotope use, and is
routinely available in only a few medical centers [1]. In
clinical practice, GFR is usually estimated from the serum
creatinine concentration. However, this last is affected by
factors other than creatinine glomerular filtration, such as
diet, muscle mass, tubular secretion, unstable renal func-
tion, colorimetric interference, and day-to-day assay vari-
ability [1]. To circumvent these limitations, several
equations have been developed to estimate GFR from the
serum creatinine concentration adjusted for age, sex, body
weight and demographic factors [1]. The equation pro-
posed by Cockcroft and Gault in 1976 is widely used
throughout the world [2,3]. Adjustment for body surface
area has been shown to improve the accuracy of the orig-
inal Cockcroft-Gault equation [4]. In recent years, the
Modification of Diet in Renal Disease (MDRD) group
developed three multiple regression models that
improved the prediction of GFR from the plasma creati-
nine concentration [5]. The first includes urinary urea
excretion and the second is derived from demographic
factors combined with serum creatinine, urea and albu-
min; the third, which is slightly less accurate, uses demo-
graphic factors and serum creatinine (MDRD abbreviated
equation) [5]. Finally, the Mayo Clinic team have devel-
oped a quadratic equation (MCQ) based on results of
both healthy subjects and patients with chronic renal dis-
eases [6].
The validity of these creatinine-based equations for the
follow-up of renal function in patients with known renal
disease is uncertain, notably during therapeutic interven-
tions and data on this topic are scarce [7]. Indeed, five
studies, all restricted to patients with diabetic nephropa-
thy suggested that, in patients with normal renal function
or hyperfiltration (microalbuminuric), prediction equa-
tions are not accurate enough to monitor kidney function,
whereas in chronic kidney disease (CKD) stages 2 and 3
these equations may be valid [8-12]. The aim of this study
was therefore to compare the accuracy of prediction equa-
tions (original Cockcroft and Gault equation, Cockcroft
and Gault equation adjusted for body surface area, Abbre-
viated MDRD and Mayo Clinic Quadratic Equation) for
the follow-up of non-diabetic nephropathies, by compar-
ison with inulin clearance, the gold standard for GFR esti-
mation. We analyzed data from a prospective cohort of
260 European patients with non-diabetic chronic kidney
disease [4], 126 of whom had repeated measures of their
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GFR based on inulin clearance during their long-term fol-
low-up.
Methods
Study population
We recently reported a cross-sectional investigation in
which we prospectively studied 269 European adults with
chronic renal disease (260 with non diabetic nephropa-
thies and 9 with diabetes mellitus) [4]. We also conducted
a longitudinally study of 126 patients of this cohort. These
patients had non-diabetic nephropahies (mainly glomer-
ular diseases) and had repeated measures of their GFR by
inulin clearance during long-term follow-up. A total of
452 inulin clearance assays were carried out in these
patients. All the patients gave their informed consent to
the study, which was approved by the local ethics commit-
tee.
Basing on inulin clearance, the patients were divided into
two subgroups: patients whose renal function deterio-
rated during follow-up (n = 65) and patients whose renal
function improved (n = 61).
The subgroup of patients whose renal function deterio-
rated during follow-up comprised 51 men and 14 with a
median age of 37 years (range 20–65 y). Twenty-four
patients had primary IgA nephropathy, 13 had idiopathic
membranous nephropathy, 7 had an idiopathic nephrotic
syndrome, 3 had mesangioproliferative glomerulonephri-
tis, 9 had systemic diseases (Henoch-Schönlein purpura:
4; lupus erythematosus: 2; primary sicca syndrome: 2;
ANCA vasculitis:1), 5 had hereditary nephritis (1 poly-
cystic renal disease, 1 Alport syndrome; 1 sickle cell ane-
mia, 2 miscellaneous) and 4 had inherited or acquired
urologic abnormalities of the kidneys, with no repercus-
sions on bladder voiding.
The subgroup of patients whose renal function improved
during follow-up comprised 39 men and 22 women with
a median age of 43 years (range 17–69 y). Nineteen
patients had primary IgA nephropathy, 9 had idiopathic
membranous nephropathy, 11 had an idiopathic neph-
rotic syndrome, 2 had mesangioproliferative glomeru-
lonephritis, 2 had crescentic glomerulonephritis, 7 had
systemic diseases (lupus erythematosus: 4; Behçet disease:
1; systemic sclerosis: 1, Atkinson-Clarkson syndrome 1), 2
had hypertensive nephritis (nephroangiosclerosis), 3 had
hereditary nephritis (1 polycystic renal disease, 1 thin
glomerular membrane disease, 1 Fabry disease) and 6 had
inherited or acquired urologic abnormalities of the kid-
neys with no repercussions on bladder voiding.
GFR measurements
GFR was measured in each patient by using the reference
inulin method (GFR-inulin) at the Physiology Depart-
ment of Henri Mondor University Hospital as previously
reported [5]. Briefly, an intravenous catheter was inserted
into an arm and used to draw blood samples for inulin
clearance measurement. The height and body weight of
the patient were recorded prior to an oral water load (8
ml/kg body weight). The patient was then placed in the
supine position. A priming dose of inulin (Inutest: Fresen-
ius Pharma, Linz, Austria), 0.12 mL/kg body weight of a
25% solution diluted in 130 mL of isotonic mannitol
solution, was infused intravenously (10 mL/min) into the
other arm. Then a continuous infusion of Inutest 25%
(0.32 mL/kg body weight) diluted in 250 mL of isotonic
mannitol solution was given at a rate of 0.9 mL/min. After
a 90-minute equilibration period, the bladder was emp-
tied and urine was collected for two 30-minute periods.
For inulin measurement, urine was deproteinized, the
polymer was hydrolyzed with hydrochloric acid, and a
colorimetric assay based on the Galli and Jeanmaire tech-
nique was performed. The first blood sample, taken
before the infusions, was used as a blank. GFR was calcu-
lated as the arithmetic mean of the GFR values obtained
during the two periods of urine collection. GFR-inulin
data were corrected for a standard body surface area of
1.73 m2.
Creatinine was measured in the first blood sample, taken
before the inulin infusions, using a modified Jaffe method
(Randox reagent; Bayer, Montpellier, France).
In each patient the GFR was also estimated from the
serum creatinine concentration by using the Cockcroft
and Gault equation, as follows:
With the results multiplied by 0.85 for females; where age
is in years, weight in kg and serum creatinine in micro-
mol/L [2,3].
GFR was also estimated with a modified Cockcroft and
Gault formula taking body surface area (BSA) into
account, as follows [4]:
The body surface area was calculated with the Dubois and
Dubois equation [13]
The following abbreviated MDRD equation was used [5]
Mayo clinic Quadratic equation [6] =
GFR - Cockcroft - Gault =
−×
×
() 140 age body weight
serum creatinine 0 0 814 . f o r  m a l e s
BSA - modified - Cockcroft - Gault formula =
× 17 3 2 . m GFR-Cockcroft-G Gault formula mL
BSA of the patient  m
(/ m i n )
() 2
186 0 742
1 154 0 203 ×× ×
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serum creatinine is expressed in mg/dl; if SCr < 0.8 mg/dl,
use 0.8 for SCr
Statistical analyses
As inulin clearance and GFR estimates were normally dis-
tributedin the overall population, we used repeated-meas-
ures analysis of variance with the Dunnet multiple
comparisons test as post-test (Instat 3, GraphPad, San
Diego USA). Correlations among the five GFR methods
were studied by using the Pearson linear coefficient of cor-
relation and coefficient of determination (Instat 3, Graph-
Pad, San Diego USA). Paired comparisons of inulin
clearance were performed with the paired t test, whereas
paired comparison of creatinine used the Wilcoxon test
(Instat 3, GraphPad, San Diego USA). The accuracy of the
GFR estimates in the whole group was assessed in terms of
the proportion of predicted values falling within 10%,
30% and 50% of the true GFR measured by inulin clear-
ance.
In each of the two study subgroups (patients whose renal
function deteriorated and those whose renal function
improved), the annual slope of GFR (change in GFR in
ml/min/1.73 m2/year) was used, as advocated by
Fontseré and coworkers [11], to assess the variability of
the prediction equations compared with the inulin
method during follow-up. The annual GFR slope was
determined for each GFR-inulin and with each prediction
equation as the loss or gain in the glomerular filtration
rate during the study period, with respect to baseline val-
ues at the start of follow-up, and standardized for 12
months [11].
As the values did not have a Gaussian distribution in the
Kolmogorov and Smirnov test; [14](Instat 3, GraphPad,
San Diego USA), we used the non parametric repeated-
measure analysis of variance (Friedman Test) with the
Dunn's multiple comparisons test as post-test to compare
the five GFR methods for determining the annual slope
[14](Instat 3, GraphPad, San Diego USA). P values < 0.05
were considered significant [14]. Correlations among the
four GFR methods for determining the slope were studied
with Spearman's rank-order correlation coefficient [14].
We then performed a concordance study as described by
Bland and Altman, in which the differences between the
methods are plotted against their mean values [15] (Prism
4, GraphPad, San Diego USA). The ability of a creatinine-
based equation to properly categorize the trend in GFR
was defined as the proportion of patients defined by the
inulin clearance as having either improved or deteriorated
renal function and who were correctly identified as such
by the GFR estimate. The proportions of correctly catego-
rized patients were compared by using the X2 test [14]
(Instat 3, GraphPad, San Diego USA). The characteristics
of the patients were analyzed using either analysis of var-
iance (parametric or non parametric according to the
Gaussian distribution), a t test or the X2 test. Finally, we
used receiver-operator characteristic (ROC) curves to
examine the ability of the estimates to discriminate pro-
gressors from improvers (Prism 4 software, Graphpad,
San Diego, USA). Values in the text and tables are means
± SD or medians and ranges, depending on the normality
of the distribution.
Results
Whole group of patients
Among the 126 patients, inulin clearance values at the
start of follow-up were distributed as follows: 24% (n =
31) in stage I, 40% (n = 50) in stage II, 30% (n = 38) in
stage III and 6% (n = 7) in stage IV of CKD, as defined by
K-DOQI [7]. Analytical data on the whole group and sub-
groups are summarized in table 1.
Repeated-measured ANOVA showed that the differences
among the five GFR methods at baseline were not due to
chance (p < 0.0001). The Dunnett multiple comparison
post-test showed a significant difference between inulin
clearance and the standard Cockcroft and Gault estimate
(t = 3.65; p < 0.01), the abbreviated MDRD equation (t =
5.59; p < 0.01), the Mayo Quadratic Equation (t = 11.83;
p < 0.01), but not the BSA-modified Cockcroft and Gault
estimate (t = 1.70; p > 0.05). These results are similar to
those previously published for an entire cohort of 269
European adults with chronic renal disease [4].
Pearson's coefficient showed that inulin clearance corre-
lated better with the BSA-modified Cockcroft and Gault
formula (r = 0.89; 95% confidence interval: 0.84–0.92; r
squared = 0.79), the Mayo Quadratic equation (r = 0.88;
95% confidence interval: 0.83–0.91; r squared = 0.77)
and the abbreviated MDRD equation (r = 0.87; 95% con-
fidence interval: 0.82–0.90; r squared = 0.75) than with
the standard Cockcroft and Gault equation (r = 0.83; 95%
confidence interval: 0.76–0.87; r squared = 0.69).
In the whole population the BSA-modified Cockcroft and
Gault formula, the abbreviated MDRD equation and the
original Cockcroft and Gault estimate were significantly
more accurate than the Mayo Quadratic equation: more
than 92.8% of the GFR values predicted by the BSA-mod-
ified Cockcroft and Gault formula fell within 30% of the
corresponding inulin clearance values, as compared to
89.7% with the abbreviated MDRD equation, 85% with
the standard Cockcroft and Gault estimate but only
67.4% with the Mayo Quadratic equation (p < 0.01 in the
X2 test). Accuracy is reported in Table 2.
Inulin clearance and creatinine values did not differ in the
whole group at the end of follow-up as compared to the
basal values (p > 0.05 in the t test and Wilcoxon testBMC Nephrology 2009, 10:16 http://www.biomedcentral.com/1471-2369/10/16
Page 4 of 10
(page number not for citation purposes)
respectively) (Table 1). The GFR slope determined by inu-
lin clearance for the whole group was low (-0.3 ml/min/
year; range: -72 – +99) and did not differed significantly
from that calculated with the GFR estimates (p > 0.05 in
the Friedman test)(Cockcroft equation: – 0.12 ml/min/
year; range: -60 – +102) (Cockcroft-BSA equation:
-0.18 ml/min/year; range: -60 – +109) (MDRD abbrevi-
ated equation: – 0.12 ml/min/year; range: -64 – +138)
(Mayo Quadratic Equation: – 0.55 ml/min/year; range: -
78 – +52). These results are explained by the fact that
about half of the patients were progressors for renal failure
whereas renal function improved symmetrically in the
other half.
The accuracy of the prediction equations expressed as the
GFR slope (ml/min/1.73 m2/year) in each of the two
groups of patients (patients with a deterioration in renal
function and patients with an improvement) is summa-
rized in Tables 3 and 4.
Patients whose renal function deteriorated
During a mean follow-up of 42.86 months (+/- 29.47;
range: 6–117), 256 determinations of GFR by inulin clear-
ance were performed in these 65 patients and the median
number of GFR per patient was 3 (range 2–11). The mean
baseline GFR determined by inulin clearance was 75.30
ml/min/1.73 m2 (+/- 26.15; range: 20–138) and the
mean baseline serum creatinine was 123 micromol/L (+/-
57.85; range: 49–316). In this group the median GFR
slope determined by inulin clearance was – 3.72 ml/min/
1.73 m2/year (range -0.48 to -72) (Tables 1 and 3).
Seventeen (26%), fifteen (23%) and sixteen (25%) of
these 65 patients were wrongly classified as having no
deterioration in renal function by the original Cockcroft-
Gault formula and the Mayo Quadratic equation, the BSA-
modified Cockcroft and the abbreviated MDRD equation
respectively (Table 4). The predictive performance of the
three GFR estimates for detecting a deterioration in renal
function did not differ significantly (p > 0.05 in the X2
test).
Table 1: Analytical data on 126 patients with non diabetic nephropathies at baseline and at the last observation during follow-up.
Sample 
Size
Age
(years)
Follow-up
(months)
Baseline GFR
(ml/min/1.73 m2)
(inulin clearance)
Baseline 
creatinine
(μmol/L)
Number of 
GFR 
measurements
Final GFR
(ml/min/1.73 m2)
(inulin clearance)
Final 
Creatinine
(μmol/L)
Whole group 126 40.36 ± 
12.48
[17–69]
37.56 ± 
27.04
[6–117]
71.03 ± 24.02
[20–138]
119.03 ± 
50.85
[49–319]
3.43 ± 2.06
[2–11]
71.19 ± 26.93
[18–140]
123.24 ± 
69.195
[53–485]
Patients with 
deterioration 
in renal 
function
65 39.15 ± 
12.50
[20–65]
42.86 ± 
29.47
[6–117]
75.30 ± 26.15
[20–138]
123.15 ± 
57.85
[49–316]
3.72 ± 2.2
[2–11]
61.67 ± 25.49
[18–118]
141.81 ± 
85.97
[63–485]
Patients with 
improvement 
in renal 
function
61 41.65 ± 
12.43
[17–69]
31.91 ± 
23.11
[6–93]
66.47 ± 20.78
[24–124]
114.81 ± 
42.21
[53–285]
3.13 ± 1.8
[2–10]
81.32 ± 24.79
[25–140]
103.45 ± 
36.31
[53–247]
Data are expressed as means ± SD [range]
Table 2: Proportion of estimated GFR values within 10% (accuracy 10%), 30% (accuracy 30%) and 50% (accuracy 50%) of the 
coresponding inulin clearance value.
Accuracy 10% (95% CI) Accuracy 30% (95% CI) Accuracy 50% (95% CI)
Cockcroft-Gault formula 43.6% [35% – 52%] 41.3% [33% – 50%] 15% [9% – 22%]
BSA-Cockcroft Gault formula 53.2% [44% – 61%] 39.6% [31% – 48%] 7.1% [3.6% – 13%]
Abbreviated MDRD equation 37.3% [29% – 46%] 52.4% [43% – 60%] 10.3% [6% – 16,9%]
Mayo Clinic Quadratic equation 27.7% [20% – 36%] 39.7% [31% – 48%] 32.6% [24% – 41%]BMC Nephrology 2009, 10:16 http://www.biomedcentral.com/1471-2369/10/16
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The Friedman test showed no difference among the five
GFR methods for the determination of the GFR slope (p =
0.29) (Table 3). The Spearman rank correlation showed
that inulin clearance correlated similarly with the stand-
ard Cockcroft and Gault equation (r = 0.64; 95% confi-
dence interval: 0.43–0.78), the BSA-modified Cockcroft
and Gault formula (r = 0.67; 95%; confidence interval:
0.46–0.80) and the abbreviated MDRD equation (r =
0.63; 95% confidence interval: 0.41–0.78) but less with
the Mayo Quadratic equation (r = 0.49; 95% confidence
interval: 0.23–0.69) (Table 4). Concordance studies with
the Bland and Altman test showed a similar bias with the
standard Cockcroft-Gault estimate (versus inulin clear-
ance: mean bias = 0.98 ml/min/1.73 m2/year), the BSA-
modified Cockcroft-Gault estimate (versus inulin clear-
ance: mean bias = 1.37 ml/min/1.73 m2/year), the Abbre-
viated MDRD (versus inulin clearance mean bias = 1.30
ml/min/1.73 m2/year) and the Mayo Quadratic equation
(versus inulin clearance mean bias = 1.32 ml/min/1.73
m2/year) (Table 4). The precision of the GFR estimates
was similar with the standard Cockcroft and Gault equa-
tion (SD of bias: 6.08 ml/min/1.73 m2/year), the BSA-
modified Cockcroft and Gault formula (SD of bias: 6.88
ml/min/1.73 m2/year) and the abbreviated MDRD (SD of
bias: 5.95 ml/min/1.73 m2/year) and larger with the
Mayo Quadratic equation (SD of bias: 13.61 ml/min/1.73
m2/year) (Table 4).
Forty-two of these progressor patients had 3 or more
repeated GFR measures (median 5; range 3–10) and were
followed-up for a median of 60 months (range: 6–117).
In these patients, the Friedman test also showed no differ-
ence among the five GFR methods for the determination
of the GFR slope (p > 0.05). The Spearman rank correla-
tion showed that inulin clearance correlated better with
the GFR estimates in these patients with longer follow-up:
standard Cockcroft and Gault equation (r = 0.67; 95%
confidence interval: 0.41–0.83); BSA-modified Cockcroft
and Gault formula (r = 0.74; 95%; confidence interval:
0.52–0.87); abbreviated MDRD equation (r = 0.79; 95%
confidence interval: 0.60–0.89); Mayo Quadratic equa-
tion (r = 0.71; 95% confidence interval: 0.46–0.85). Sim-
ilarly, concordance studies with the Bland and Altman test
showed a smaller bias with the standard Cockcroft-Gault
Table 3: Comparison of predictive equations during follow-up in CKD patients with non-diabetic nephropathies.
Method of GFR estimation Slope of GFR
(ml/min/1.73 m2/year)
Median and [range]
p value in the Friedman test
(non parametric ANOVA)
P value in Dunn's multiple 
comparison post-test
Subgroup of patients with 
deteriorating renal function
(n = 65)
Inulin Clearance -3.72 [-0.48 to -72]
GFR Cockcroft-Gault -4.08 [-0.36 to -60] NS
BSA-modified Cockcroft-
Gault Formula
-3.48 [-0.24 to -56] p = 0.29 NS
Abbreviated MDRD 
equation
-3.12 [0 to -64] NS
Mayo Clinic Quadratic 
equation
-3.73 [0 to -78] NS
Subgroup of patients with 
improving renal function
(n = 61)
Inulin Clearance +6 [+0.36 to +99]
GFR Cockcroft-Gault +4.2 [0 to +102] p < 0.001 p < 0.05
BSA-modified Cockcroft-
Gault Formula
+3.36 [+0.12 to +109] p < 0.05
Abbreviated MDRD 
equation
+5.04 [0 to +138] p < 0.05
Mayo Clinic Quadratic 
equation
+4.74 [0 to +53] p < 0.05BMC Nephrology 2009, 10:16 http://www.biomedcentral.com/1471-2369/10/16
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estimate (versus inulin clearance: mean bias = 0.47 ml/
min/1.73 m2/year), the Mayo Quadratic equation (versus
inulin clearance mean bias = 0.45 ml/min/1.73 m2/year),
and the BSA-modified Cockcroft-Gault estimate (versus
inulin clearance: mean bias = 1.19 ml/min/1.73 m2/year),
and a similar bias with the Abbreviated MDRD (versus
inulin clearance mean bias = 1.43 ml/min/1.73 m2/year).
The precision of the GFR estimates was also improved in
the standard Cockcroft and Gault equation (SD of bias:
4.45 ml/min/1.73 m2/year) but similar in the BSA-modi-
fied Cockcroft and Gault formula (SD of bias: 6.65 ml/
min/1.73 m2/year), the abbreviated MDRD (SD of bias:
5.98 ml/min/1.73 m2/year) and the Mayo Quadratic
equation (SD of bias: 11.57 ml/min/1.73 m2/year). The
improvement in the performance of these equations in
patients followed-up for a longer period and having more
GFR measurements strongly suggests regression toward
the mean, a well-known statistical phenomenon where
extreme scores regress toward the mean when remeasured
[14].
Patients with an improvement in renal function
During a mean follow-up of 31.91 months (+/- 23.11;
range: 6–93) these 61 patients had 196 determinations of
GFR by inulin clearance and the median number of GFR
per patient was 2 (range 2–10). The mean baseline GFR
determined by inulin clearance was 66.47 ml/min/1.73
m2 (+/- 20.78; range: 24–124) and the mean baseline
serum creatinine was 114.81 micromol/L (+/- 42.21;
range: 53–285) (Table 1). In this group, the median GFR
slope determined by inulin clearance was + 6 ml/min/
1.73 m2/year (range +0.36 to +99) (Table 1). Sixteen of
these 61 patients (26%) were wrongly classified as having
no improvement in renal function by the original and
BSA-adjusted Cockcroft-Gault formulas; respectively 20
patients (32%) and 21 patients (34%) were wrongly clas-
sified by the Mayo Quadratic equation and the abbrevi-
ated MDRD equation (Table 4). The predictive
performance of the three GFR estimates for detecting an
improvement in renal function did not differ significantly
(p > 0.05 in the X2 test).
The Friedman test showed that the differences among the
five GFR methods for the determination of the GFR slope
Table 4: Assessment of GFR changes with time using the original Cockcroft and Gault formula (CG), the BSA-modified-Cockcroft and 
Gault formula (BSA-CG) and the Abbreviated MDRD equation (A-MDRD), and the Mayo Clinic Quadratic equation.
Original Cockcroft 
and Gault formula 
(CG)
BSA-modified-
Cockcroft and 
Gault formula 
(BSA-CG)
Abbreviated 
MDRD equation 
(A-MDRD)
Mayo Clinic 
Quadratic equation 
(MCQ)
Subgroup of 
patients with 
deteriorating renal 
function
(n = 65)
Spearman Correlation 
coefficient (95% 
confidence interval) 
with inulin clearance
r = 0.64 (0.43 – 0.78) r = 0.67 (0.46 – 0.80) r = 0.63 (0.41 – 0.78) r = 0.49 (0.23 – 0.69)
Patients correctly 
classified as having 
deteriorating renal 
function
74% 77% 75% 74%
Bias (SD of bias) 
versus inulin clearance
0.98 (6.08) 1.37 (6.88) 1.30 (5.95) 1.32 (13.61)
Subgroup of 
patients with 
improving renal 
function
(n = 61)
Spearman Correlation 
coefficient (95% 
confidence interval) 
inulin clearance
0.75 (0.58 – 0.86) r = 0.75 (0.58 – 0.86) r = 0.72 (0.54 – 0.84) r = 0.46 (0.19 – 0.67)
Patients correctly 
classified as having 
improving renal 
function
74% 74% 66% 68%
Bias (SD of bias) 
versus inulin clearance
3.08 (7.98) 2.98 (7.63) 1.27 (8.87) 3.02 (15.46)BMC Nephrology 2009, 10:16 http://www.biomedcentral.com/1471-2369/10/16
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were not due to chance (p < 0.0005)(Table 3). Dunn's
multiple comparison post-test showed a significant differ-
ence between inulin clearance and the standard Cockcroft
and Gault estimate (p < 0.05), the BSA-modified Cock-
croft and Gault estimate (p < 0.05), the Abbreviated
MDRD equation (p < 0.05) and the Mayo Quadratic
Equation (p < 0.05)(Table 3). The Spearman rank correla-
tion showed that inulin clearance correlated similarly
with the standard Cockcroft and Gault equation (r = 0.75;
95% confidence interval: 0.58–0.86), the BSA-modified
Cockcroft and Gault formula (r = 0.75; 95% confidence
interval: 0.58–0.86), the Abbreviated MDRD equation (r
= 0.72; 95% confidence interval: 0.54–0.84), but less with
the Mayo Quadratic equation (r = 0.46; 95% confidence
interval: 0.19–0.67) (Table 4). Concordance studies with
the Bland and Altman test showed similar bias with the
standard Cockcroft-Gault estimate (versus inulin clear-
ance: mean bias = 3.08 ml/min/1.73 m2/year), the BSA-
modified Cockcroft-Gault estimate (versus inulin clear-
ance: mean bias = 2.98 ml/min/1.73 m2/year), the Mayo
Quadratic equation (versus inulin clearance: mean bias =
3.02 ml/min/1.73 m2/year) but a smaller bias with the
abbreviated MDRD (versus inulin clearance: mean bias =
1.27 ml/min/1.73 m2/year)(Table 4). The precision of the
GFR estimates was similar with the standard Cockcroft
and Gault equation (SD of bias: 7.98 ml/min/1.73 m2/
year), the BSA-modified Cockcroft and Gault formula (SD
of bias: 7.63 ml/min/1.73 m2/year), the abbreviated
MDRD (SD of bias: 8.87 ml/min/1.73 m2/year) and larger
for the Mayo Quadratic equation (SD of bias: 15.46 ml/
min/1.73 m2/year) (Table 4).
Twenty-one of these patients had 3 or more repeated
measures (median 5; range: 3–10) and were followed-up
for a median of 65 months (range: 16–107). Interestingly,
in these patients, the Friedman test also showed no differ-
ence among the five GFR methods for the determination
of the GFR slope (p = 0.10). The Spearman rank correla-
tion showed that inulin clearance also correlated better
with the GFR estimates in these patients with longer fol-
low-up; standard Cockcroft and Gault equation (r = 0.86;
95% confidence interval: 0.67–0.94); BSA-modified
Cockcroft and Gault formula (r = 0.88; 95%; confidence
interval: 0.72–0.95); abbreviated MDRD equation (r =
0.80; 95% confidence interval: 0.54–0.92); the Mayo
Quadratic equation (r = 0.72; 95% confidence interval:
0.40–0.88). Similarly, concordance studies with the Bland
and Altman test showed a smaller bias with the Abbrevi-
ated MDRD (versus inulin clearance mean bias = 0.61 ml/
min/1.73 m2/year), the standard Cockcroft-Gault esti-
mate (versus inulin clearance: mean bias = 2.06 ml/min/
1.73 m2/year), and the BSA-modified Cockcroft-Gault
estimate (versus inulin clearance: mean bias = 2.04 ml/
min/1.73 m2/year) and a similar bias with the Mayo
Quadratic equation (versus inulin clearance mean bias =
3.28 ml/min/1.73 m2/year).
The precision of the GFR estimates was also improved in
the standard Cockcroft and Gault equation (SD of bias:
6.88 ml/min/1.73 m2/year) and the BSA-modified Cock-
croft and Gault formula (SD of bias: 6.87 ml/min/1.73
m2/year) and similar with the abbreviated MDRD (SD of
bias: 10.94 ml/min/1.73 m2/year) and the Mayo Quad-
ratic equation (SD of bias: 15.98 ml/min/1.73 m2/year).
The improvement in the performance of these equations
in these improved patients followed-up for a longer
period also strongly suggests a regression toward the
mean [14].
Characteristics of the patients
Progressors differed from improvers by higher proteinuria
at the outset of the study (p < 0.005 Kruskal-Wallis test
with Dunn's multiple comparisons test; Progressors: 1.17
g/24 h (range: 0.32–20); Improvers: 0.5 g/24 h (range:
0.10–19.70)). The percentages of patients receiving
immunological treatment and drugs acting on the renin-
angiotensin system were similar in the group of progres-
sors and in the group of improvers (p > 0.05 in the X2
test).
The inaccuracy of the formulae for classifying patients as
improvers or progressors was not related to any of the fol-
lowing clinical features: age (p > 0.05 in the t test), weight
(p > 0.05 in the t test), sex (p > 0.05 in the X2 test), histo-
logical type of the renal disease (p > 0.05 in the X2 test).
The area under the ROC curves for discriminating
between progressors and improvers were very close for the
4 GFR estimates: 0.79 (95% confidence interval: 0.70–
0.87) for the original Cockcroft and Gault Equation; 0.79
(95% confidence interval: 0.71–0.87) for the BSA-modi-
fied Cockcroft and Gault formula; 0.78 (95% confidence
interval: 0.70–0.86) for the abbreviated MDRD equation
and 0.77 (95% confidence interval: 0.68–0.85) for the
Mayo Quadratic equation.
Discussion
In 126 adults with non-diabetic chronic renal disease
(mainly glomerular diseases), we estimated the time
course of the glomerular filtration rate with the gold-
standard method (inulin clearance). In patients with dete-
riorating renal function, the original Cockcroft and Gault
formula, the BSA-modified Cockcroft and Gault formula,
the abbreviated MDRD equation and the Mayo Quadratic
equation all gave reliable estimates of the GFR slope, with
an acceptable bias. In contrast in the patients with
improving renal function, the original Cockcroft and
Gault formula, the BSA-modified Cockcroft and Gault for-
mula, the abbreviated MDRD equation and the MayoBMC Nephrology 2009, 10:16 http://www.biomedcentral.com/1471-2369/10/16
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Quadratic equation underestimated the gain in GFR,
although this may have less important clinical conse-
quences. In the subgroup of patients with improving renal
function, the underestimation of the slope was smaller
with the abbreviated MDRD equation than with the other
three equations.
To date, GFR equations have been developed and vali-
dated almost exclusively with cross-sectional data sets.
The Cockcroft and Gault formula is an estimate of creati-
nine clearance originally developed in a population of
236 Canadian patients, 209 of whom were male [2]. The
Cockcroft and Gault formula was further shown to be a
reliable estimate of GFR in twelve studies comparing the
results of the estimate with methods giving true GFR val-
ues (inulin; 2 studies with 196 patients) or more accurate
GFR values (10 studies with 1218 patients; 3 studies with
99m-Tc-DPTA; 4 studies with 51Cr-EDTA; 2 with iothala-
mate, 1 with hippuran (reviewed in [3,4]). Three studies,
one published in 1984 [16] using iothalamate, an isotope
with significant tubular secretion [17], the second in
1992, in a small cohort of 20 patients with type I diabetes
[18] and the third comparing inulin clearance in a cohort
of 269 European patients with chronic nephropathies [4],
have shown that correction for body surface area (BSA)
improves the accuracy of the original Cockcroft and Gault
equation.
The MDRD formulas were developed as an estimate of
125I-Iothalamate clearance-based GFR in a population of
1628 patients with a diagnosis of CKD [5]. The MDRD
equations yielded smaller median absolute errors (3.8
mL/min/1.73 m2) than the Cockcroft and Gault equation
(6.8 mL/min/1.73 m2) in the princes study [11]. In recent
studies conducted in France with 51Cr-EDTA, the MDRD
equation was more accurate for the diagnosis and stratifi-
cation of renal failure in diabetic type II patients [19,20].
Finally, despite the fact that the MDRD equations were
developed in patients with heavily impaired renal func-
tion (CKD stages 3 and 4) [5], the abbreviated MDRD for-
mula has been shown to properly categorize patients with
CKD stage 2, and has fairly good accuracy in these patients
[4,21,22].
The Mayo clinic quadratic equation is a new equation
based on the results of iothalamate clearance in both 320
patients with chronic kidney diseases and 580 healthy
subjects evaluated for kidney donation [6]. Elderly sub-
jects and African-Americans were underrepresented in this
sample [6]. The Mayo quadratic equation was further
shown to have similar diagnostic performance to the
MRDD equation in diabetic patients; in contrast to
MDRD equation, the Mayo quadratic equation does not
underestimate normal GFR in diabetic subjects [23];
As previously discussed, five studies, all restricted to
patients with type I and II diabetes, have shown the poor
accuracy of prediction equations for monitoring kidney
function, unless frank renal impairment has occurred [8-
12].
One study in lung transplant patients compared longitu-
dinal follow-up based on creatinine-based formulas
(Cockcroft and Gault equation and MDRD equation 7)
with the Iothalamate GFR for at least 24 months, and con-
cluded that the creatinine-based slopes correlated with
Iothalamate slopes in this setting but consistently under-
estimated the rate of GFR decline [24]. Similar conclu-
sions were recently drawn in study of kidney transplant
patients [25]. A post-hoc analysis of the African American
Study of Kidney Disease and Hypertension (AASK) has
recently shown that outcomes based on the AASK creati-
nine formula and the MDRD equations were similar to
those obtained with 125I-Iothalamate GFR and similarly
identified most risk factors for progression of renal failure
[26]. Conversely, in a cohort of 234 patients with auto-
somal dominant polycystic kidney disease and a baseline
creatinine clearance > 70 ml/min followed for 4 years,
although Iothalamate clearance, the abbreviated MDRD
equation and the Cockcroft-Gault formula gave similar
slopes, predictor associations for renal function decline
were strongest with iothalamate clearance, because non-
GFR factors (e.g. creatinine production and tubular secre-
tion) conservatively biased associations with GFR esti-
mates [27]. Moreover, in a retrospective cohort study of
542 subjects who had been included in the MDRD study
and followed for a median of 2.6 years, the estimated GFR
slope tended to underestimate measured decrements in
125I-Iothalamate GFR [28]. The main methodological lim-
itations of these latter studies was the use of 125I-Iothala-
mate for GFR measurement indeed, Odlind and
coworkers have shown that this isotope is subject to sig-
nificant tubular secretion in chicken, rats and humans
[17]. The tubular secretion of iothalamate becomes even
marked in case of renal failure and can overestimate GFR
by up to 34%; these authors stated that iothalamate is not
an ideal reference substance for GFR determinations in
clinical studies, with an accuracy comparable to that of
creatinine [17].
The main limitation of our study lies in the day-to-day
variations that are known to occur in inulin clearance
(11%–16%), and in serum creatinine (15.5%–19.6%)[5].
Furthermore, we did not pay special attention to the cali-
bration of serum creatinine measurements, which has
been shown to be of critical importance in individuals
with normal or near-normal serum creatinine values, and
to influence the accuracy of MDRD equations [29-31]. In
clinical trials, accurate determination of the glomerular
filtration rate and correct evaluation of changes in renalBMC Nephrology 2009, 10:16 http://www.biomedcentral.com/1471-2369/10/16
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function are mandatory and require direct GFR measure-
ment with inulin, isotopes or radiocontrast media [32]. In
contrast, clinicians require a less expensive and less time-
consuming test than direct GFR measurement, and
although the results should be accurate, they do not need
to be as precise as in clinical trials. The accuracy of the cre-
atinine-based formula for follow-up of chronic nephropa-
thies could be improved by calibrating serum creatinine
measurements (see discussion above) [29-31] and by
using cimetidine combined with an enzymatic plasma
creatinine assay which has been shown in a longitudinal
study of type II diabetic nephropathy to abolish the dis-
crepancies between the iothalamate slope and the original
Cockcroft and Gault equation [33]. Finally, for patients at
an early phase of reduction of GFR reduction (CKD stage
1 and 2) and those whose GFR is improving, because of its
higher diagnostic accuracy in patients with mildly to mod-
erately impaired kidney function, cystatin C may provide
useful additional information relative to the Cockcroft
and Gault formulas and MDRD equations [34,35].
Indeed, an equation combining both serum creatinine
and cystatin levels with demographic and morphologic
data was recently shown in children to have better accur-
ancy than the Schwartz equation when compared to EDTA
clearance [36]. Similarly, in Chinese patients with near-
normal renal function, a GFR estimate combining serum
creatinine and cystatin C matched DTPA-clearance more
closely than MDRD equations [37]. Preliminary data
strongly suggest that a combination of cystatin C and
serum creatinine also improves the monitoring of kidney
function in patients with diabetes mellitus [38]. Finally, in
a pooled analysis of 3418 subjects with CKD of various
stages living in the USA and France and evaluated for GFR
by isotope clearance (iothalamate and EDTA), an equa-
tion including serum cystatin in combination with serum
creatinine, age, sex and race provided a more accurate esti-
mate of GFR than cystatin or creatinine alone [39].
Conclusion
In patients with non diabetic nephropathies (mainly
glomerular diseases) and deteriorated renal function, the
original Cockcroft and Gault formula, the BSA-modified
Cockcroft and Gault formula, the abbreviated MDRD
equation and the Mayo Quadratic equation give reliable
estimates of the GFR slope with an acceptable bias. In the
subgroup of patients with an improvement in renal func-
tion, these creatinine-based formulas underestimate the
gain in GFR although this may have less important clinical
consequences.
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